OBJECTIVES: The aims of our study were to assess the prevalence of QTc prolongation in a group of HIV-infected individuals and to evaluate the associated risk factors. METHODS: All the 650 HIV-infected patients followed up at our outpatient clinic underwent ECG recording. A "nested" case-control study was performed using as cases 64 HIV-infected patients with QTc > 0.44 s and as controls (1:4) 256 HIV-positive subjects matched by gender and age with QTc interval < or = 0.44 s. RESULTS: A prolonged QTc interval was found in 9.8% of HIV-positive individuals (64/650). In the nested case-control study, an increased risk of having a prolonged QTc interval was observed among patients taking nelfinavir, efavirenz, methadone, cotrimoxazole or an excessive amount of alcohol. When a zidovudine (AZT)-containing backbone was associated with nelfinavir-based or efavirenz-based antiretroviral therapy, the risk of having a prolonged QTc interval was about three times higher than in patients taking nelfinavir or efavirenz without AZT. CONCLUSIONS: Several drugs administered to HIV-infected patients may cause a QTc interval prolongation increasing the risk of serious arrhythmias. An ECG follow-up for the assessment of QTc seems to be advisable for HIV-infected patients receiving drugs with a QTc prolonging potential.
OBJECTIVES: The aims of our study were to assess the prevalence of QTc prolongation in a group of HIV-infected individuals and to evaluate the associated risk factors. METHODS: All the 650 HIV-infectedpatients followed up at our outpatient clinic underwent ECG recording. A "nested" case-control study was performed using as cases 64 HIV-infectedpatients with QTc > 0.44 s and as controls (1:4) 256 HIV-positive subjects matched by gender and age with QTc interval < or = 0.44 s. RESULTS: A prolonged QTc interval was found in 9.8% of HIV-positive individuals (64/650). In the nested case-control study, an increased risk of having a prolonged QTc interval was observed among patients taking nelfinavir, efavirenz, methadone, cotrimoxazole or an excessive amount of alcohol. When a zidovudine (AZT)-containing backbone was associated with nelfinavir-based or efavirenz-based antiretroviral therapy, the risk of having a prolonged QTc interval was about three times higher than in patients taking nelfinavir or efavirenz without AZT. CONCLUSIONS: Several drugs administered to HIV-infectedpatients may cause a QTc interval prolongation increasing the risk of serious arrhythmias. An ECG follow-up for the assessment of QTc seems to be advisable for HIV-infectedpatients receiving drugs with a QTc prolonging potential.
Authors: Gerald S Bloomfield; Isabelle R Weir; Heather J Ribaudo; Kathleen V Fitch; Carl J Fichtenbaum; Laura E Moran; Roger Bedimo; Christopher de Filippi; Caryn G Morse; Jonathan Piccini; Markella V Zanni; Michael T Lu; Udo Hoffmann; Steven K Grinspoon; Pamela S Douglas Journal: J Acquir Immune Defic Syndr Date: 2022-03-01 Impact factor: 3.771
Authors: Alexander Shimabukuro-Vornhagen; Jan Rybniker; Shahram Zoghi; Gerd Faetkenheuer; Guido Michels; Erland Erdmann; Michael von Bergwelt-Baildon; Matthias Kochanek Journal: Case Rep Med Date: 2010-08-23
Authors: Ahmed M Abdelhady; Tyler Shugg; Nancy Thong; Jessica Bo Li Lu; Yvonne Kreutz; Heather A Jaynes; Jason D Robarge; James E Tisdale; Zeruesenay Desta; Brian R Overholser Journal: J Cardiovasc Electrophysiol Date: 2016-07-25
Authors: Katherine C Wu; Long Zhang; Sabina A Haberlen; Hiroshi Ashikaga; Todd T Brown; Matthew J Budoff; Gypsyamber D'Souza; Lawrence A Kingsley; Frank J Palella; Joseph B Margolick; Otoniel Martínez-Maza; Elsayed Z Soliman; Wendy S Post Journal: Heart Date: 2018-10-26 Impact factor: 5.994
Authors: Elsayed Z Soliman; Jens D Lundgren; Mollie P Roediger; Daniel A Duprez; Zelalem Temesgen; Markus Bickel; Judith C Shlay; Charurut Somboonwit; Peter Reiss; James H Stein; James D Neaton Journal: AIDS Date: 2011-01-28 Impact factor: 4.177